1253641-65-4

CB1 antagonist 4 (compound 8) is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist. CB1 antagonist 4 shows limited penetrance to the brain in order to minimize or prevent CNS adverse reactions, and preserves potential antiobesity effects. CB1 antagonist 4 reduces propensity for psychiatric side effects[1][2].

TM38837 is a peripherally selective cannabinoid receptor type 1 (CB1) receptor antagonist. It has limited brain penetration to minimize or prevent CNS adverse effects and retain potential anti-obesity effects. Also it can reduces the propensity for psychotic side effects.

CB1

CB1

Store at -20°C

[1] Micale V, et al. The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows ReducedFear-Promoting Effects in Mice. Front Pharmacol. 2019 Mar 20;10:207. DOI:10.3389/fphar.2019.00207
[2] Klumpers LE, et al. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol. 2013 Dec;76(6):846-57. DOI:10.1111/bcp.12141